{'fraction_non_alphanumeric': 0.03860160233066278, 'fraction_numerical': 0.013838310269482883, 'mean_word_length': 5.702439024390244, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Neurogenic differentiation capacity of subacromial bursal tissue—derived stem cells

In this study, analysis and comprehensive comparison of neurogenic differentiation capacity of human bursal tissue‐derived‐stem cells (hBT‐SCs) was aimed with human bone marrow derived mesenchymal stem cells (hBM‐MSCs). hBT‐SCs was isolated from subacromial bursa tissue (n = 3) by collagen type‐II digestion. The expression of stem cell markers, differentiation capacity and telomerase activity were determined for both cell lines. The expression levels of neurogenic cell markers were compared consecutively. With respect to the surface marker profile, both cells display similar pluripotency phenotypes. Both cells successfully differentiated into osteo‐ and adipogenic cell lines. The immune staining of mesenchymal, stem cell and neurogenic markers gave positive reaction. The gene expression level for Tubb3, Nestin, Gfap, Map2, Nf‐h, and Nf‐l was higher in hBT‐SCs than hBM‐MSCs. The high level of neurotrophic factors, like Tenascin C, NGF, BDNF, VEGF, and CNTF might indicate their regeneration and maintenance capacity in damaged neural tissue. Besides they are alternative source for human mesenchymal stem cells, hBT‐SCs assess the possibility to use in clinical studies. © 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:151–158, 2014.